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Abstract
Background and Objectives Sifalimumab is a fully human
immunoglobulin G1j monoclonal antibody that binds to and
neutralizes a majority of the subtypes of human interferon-a.
Sifalimumab is being evaluated as a treatment for systemic
lupus erythematosus (SLE). The primary objectives of this
analysis were (a) to develop a population pharmacokinetic
model for sifalimumab in SLE; (b) to identify and quantitate
the impact of patient/disease characteristics on pharmaco-
kinetic variability; and (c) to evaluate fixed versus body
weight (WT)-based dosing regimens.
Methods Sifalimumab serum concentration-time data
were collected from a phase Ib study (MI-CP152) designed
to evaluate the safety and tolerability of sifalimumab in
adult patients with SLE. Sifalimumab was administered
every 14 days as a 30- to 60-minute intravenous infusion
with escalating doses of 0.3, 1.0, 3.0, and 10 mg/kg and
serum concentrations were collected over 350 days. A total
of 120 patients provided evaluable pharmacokinetic data
with a total of 2,370 serum concentrations. Sifalimumab
serum concentrations were determined using a validated
colorimetric enzyme-linked immunosorbent assay (ELISA)
with a lower limit of quantitation of 1.25 lg/mL. Popula-
tion pharmacokinetic modeling of sifalimumab was per-
formed using a non-linear mixed effects modeling
approach with NONMEM VII software. Impact of patient
demographics, clinical indices, and biomarkers on phar-
macokinetic parameters were explored using a stepwise
forward selection and backward elimination approach. The
appropriateness of the final model was tested using visual
predictive check (VPC). The impact of body WT-based and
fixed dosing of sifalimumab was evaluated using a simu-
lation approach. The final population model was utilized
for phase IIb dosing projections.
Results Sifalimumab pharmacokinetics were best descri-
bed using a two-compartment linear model with first order
elimination. Following intravenous dosing, the typical
clearance (CL) and central volume of distribution (V1)
were estimated to be 176 mL/day and 2.9 L, respectively.
The estimates (coefficient of variation) of between-subject
variability for CL and V1 were 28 and 31 %, respectively.
Patient baseline body WT, interferon gene signature from
21 genes, steroid use, and sifalimumab dose were identified
as significant covariates for CL, whereas only baseline
body WT was a significant covariate for V1 and peripheral
volume of distribution (V2). Although the above-mentioned
covariates were statistically significant, they did not
explain variability in pharmacokinetic parameters to any
relevant extent (\7 %). Thus, no dosing adjustments are
necessary. VPC confirmed good predictability of the final
population pharmacokinetic model. Simulation results
demonstrate that both fixed and body WT-based dosing
regimens yield similar median steady state concentrations
and overall variability. Fixed sifalimumab doses of 200,
600, and 1,200 mg monthly (with a loading dose at Day
14) were selected for a phase IIb clinical trial.
Conclusion A two-compartment population pharmacoki-
netic model adequately described sifalimumab pharmacoki-
netics. The estimated typical pharmacokinetic parameters
were similar to other monoclonal antibodies without target
mediated elimination. Although the population pharmaco-
kinetic analysis identified some statistically significant
covariates, they explained\7 % between-subject variability
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in pharmacokinetic parameters indicating that these covari-
ates are not clinically relevant. The population pharmacoki-
netic analysis also demonstrated the feasibility of switching
to fixed doses in phase IIb clinical trials of sifalimumab.
1 Background
Systemic lupus erythematosus (SLE) is a prototypic sys-
temic autoimmune disease [1] characterized by acute and
chronic inflammation of various organs [2]. The disease
includes constitutional symptoms and signs; and muscu-
loskeletal, mucocutaneous, renal, pulmonary, cardiac,
hematologic, and neuropsychiatric manifestations. The
prevalence of SLE in the United States is approximately 40
to 50 cases per 100,000 people [3]. SLE may occur at any
age and in men or women, but predominantly affects
women of childbearing years [4, 5]. Overall female-to-
male ratio is about 9:1 or 10:1. About 20 % of patients
develop lupus before 16 years of age, 65 % between 16
and 65 years, and 15 % after the age of 65 years.
SLE can be a serious and life-threatening illness with a
substantial unmet medical need [6]. Belimumab (Benlysta)
is the only recently approved biologic for SLE treatment.
Patients with moderate-to-severe disease are treated with
corticosteroids [2, 7] and other agents such as azathioprine,
cyclophosphamide, or mycophenolate mofetil.
Interferons (IFNs) are classified as type I or type II [8].
Type I IFNs include IFN-a (13 subtypes) and IFNs b, x,
and j. Evidence suggests that type I IFNs have a role in SLE
[9–13]. Type I IFNs stimulate the maturation of plasmacy-
toid dendritic cells and the generation and function of natural
killer cells, T cells, and B cells. IFN-a activity is elevated in
the sera of SLE patients [11, 14]. In murine models of SLE,
type I IFN receptor deficiency appears to protect against
lupus [15]. IFN levels are strongly associated with SLE
disease activity [11, 14]. SLE patients with high anti-dsDNA
antibody titers, lupus nephritis, and progressive rashes have
high serum levels of type I IFN [14]. In addition, patients
with acute skin involvement tend to have elevated IFN in
blood and skin [11]. Treatment with IFN-a has been asso-
ciated with the development of SLE autoantibodies and
clinical features of the disease [16, 17]. Increased expression
of genes induced by type I IFNs (known as the gene
expression signature) is prominent in peripheral blood
mononuclear cells in approximately 60 % of SLE patients
and is associated with greater disease activity [9, 10, 12, 18–
20]. Skin biopsies from both the affected and unaffected skin
of patients with SLE also show increased type I IFN gene
signature [21, 22]. These data support the hypothesis that
inhibiting type I IFN may reduce disease activity in SLE.
Sifalimumab is a fully human immunoglobulin (Ig) G1j
monoclonal antibody (mAb) that binds to and neutralizes a
majority of the subtypes of human IFN-a. Sifalimumab is
being currently evaluated for the treatment of SLE. Single
intravenous dose pharmacokinetics of sifalimumab have
been evaluated in a phase I study (MI-CP126;
NCT00299819) following 0.3, 1, 3, 10, and 30 mg/kg in
mild to moderate SLE patients and multiple intravenous
dose pharmacokinetics of sifalimumab have been evaluated
in a phase Ib study (MI-CP152; NCT00482989). Pharma-
cokinetic parameters can be affected by various patient
demographics, concomitant medication, and disease status.
Therefore this population pharmacokinetic analysis was
conducted to (a) develop a population pharmacokinetic
model for sifalimumab in SLE; (b) to quantitate the ability
of various patient demographics and disease characteristics
to explain pharmacokinetic variability; and (c) compare
sifalimumab exposures after fixed and body weight (WT)-
based dosing.
2 Methods
2.1 Study Design and Patient Population
Sifalimumab serum concentration-time data were obtained
from a multicenter, randomized, double-blind, placebo-
controlled, dose-escalation phase Ib (MI-CP152) study
(with an open-label extension) designed to evaluate the
safety and tolerability of multiple intravenous doses of
sifalimumab in adult patients with SLE. The study was
conducted in compliance with the Declaration of Helsinki
and the Guidelines for Good Clinical Practice. Written
informed consent was obtained from all patients. Approx-
imately 30 to 40 international sites from North and South
America participated in this study.
In this phase Ib study (MI-CP152), a total of 161 SLE
patients were randomized in a 3:1 ratio to receive either
sifalimumab or placebo; of which 121 patients received
sifalimumab. Sifalimumab was administered as a 30- to
60-minute intravenous infusion with escalating doses of
0.3, 1.0, 3.0, and 10 mg/kg every 2 weeks for a total of 14
doses. Individual patients remained on the randomized
dose throughout the study. Venous blood samples for
measuring serum concentrations of sifalimumab were col-
lected at pre-dose, end of infusion, and 2 hours after
completion of infusion (after first and last dose on Day
182); every 2 weeks prior to drug administration (from
dose 2 through 13); and on Days 185, 189, 196, 210, 238,
266, 294, 322, and 350 post last dose.
2.2 Assay Methodology
Sifalimumab serum concentrations were determined using
a validated colorimetric enzyme-linked immunosorbent
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assay (ELISA). In the assay, microtiter plates were coated
with 0.5 lg/mL goat anti-sifalimumab idiotype antibody,
blocked with casein buffer and washed. Calibration stan-
dards (0.3–160 lg/mL) and control samples were prepared
by diluting sifalimumab reference standard into human
serum. Following incubation, plates were washed and goat
anti-human IgG conjugated with horseradish peroxidase
was added for binding of captured sifalimumab. Plates
were washed and pre-warmed 2,20-azino-bis-(3-ethyl-
benzthiazoline-6-sulfonic acid) (ABTS) peroxidase sub-
strate was added. The reaction was stopped by addition of
1 % sodium dodecyl sulfate (SDS) stop solution. Plates
were measured at a 405 nm wavelength using a Molecular
Devices SpectraMax microplate reader and the results were
analyzed using SOFTmax PRO software. The color
intensity of the reaction was proportional to the amount of
sifalimumab present in the sample. The assay lower limit
of quantitation was determined to be 1.25 lg/mL and the
upper limit of quantitation was determined to be 40 lg/mL.
2.3 Population Pharmacokinetic Analysis
A non-linear mixed-effect modeling approach [23–28] was
used to analyze sifalimumab pharmacokinetic data. The
population pharmacokinetic modeling was performed using
NONMEM Version VII software (ICON Development
Solutions, Ellicott City, MD, USA), G-Fortran (http://gcc.
gnu.org/fortran/) and Perl-speaks-NONMEM (PSN) [29,
30] (http://psn.sourceforge.net/). Data management and
graphical analyses were performed using S-plus 8.1 (TIB-
CO Software Inc., Somerville, MA, USA), Xpose 4.0
(University of Uppsala, Uppsala, Sweden) and R 2.7.1 (http://
cran.r-project.org/) software. The various steps involved in
the modeling processes are described below.
A series of structural models were evaluated based on
Akaike information criteria (AIC) value, objective function
values (OFV), precision, plausibility of parameter esti-
mates, and goodness-of-fit plots. The between-subject
variability in pharmacokinetic parameters was assumed to
follow a log-normal distribution and was modeled using
exponential functions, while the residual variability was
evaluated using heteroscedastic (proportional), or com-
bined proportional and additive models.
After the structural model was identified, covariate
model-building was carried out to assess the effect of
patient/disease characteristics on sifalimumab pharmaco-
kinetic parameters. Various patient/disease characteristics
including age, gender, ethnicity, region, baseline body WT,
baseline steroid use (BSTEROID), baseline SLE disease
activity index (BSLEDAI) score, baseline gene signature
from 21 genes (BGENE21), baseline gene signature from 4
genes (BGENE4), sifalimumab dose and immunogenicity
(IM) were evaluated. BGENE21 was the baseline gene
signature (or type I IFN-inducible transcript) from selected
21 IFN genes whose expression can be utilized as a marker
of type I IFN inducible pathway activation in SLE.
BGENE4 was the baseline gene signature from 4 IFN
genes and was a subset of BEGENE21. Missing individual
covariate values were imputed with population median
value of that particular covariate. A preliminary assessment
of covariate influence was conducted using generalized
additive modeling (GAM) approach as implemented in
Xpose [31]. Based on GAM results and mechanistic
understanding of sifalimumab disposition, the relevant
covariates for each parameter were further tested using
NONMEM for their significance. The model building was
carried out using a stepwise forward addition (p \ 0.05;
reduction in OFV [DOFV] [3.84) followed by backward
elimination (p \ 0.01; DOFV[6.63) approach. The impact
of potential covariates was first tested individually and the
most significant covariate was included in the model. In the
next steps, the remaining covariates were investigated. This
process was repeated until all significant covariates were
included in the model to form the full model (forward
selection). Then the covariates were removed from the full
model one by one. Covariates were retained in the final
model provided the covariates were reasonable based on
the pharmacology of sifalimumab and if their removal
resulted in a statistically significant increase ([6.63) in
OFV (backward elimination). The first-order conditional
estimation method with interaction option was used
throughout the modeling process. The subroutines
ADVAN3 and TRANS4 in the NONMEM library were
used for modeling.
The relationship between continuous covariates and
pharmacokinetic parameters was modeled using non-linear
power functions (Eq. 1) with the covariate normalized to
the population median for the data set. The categorical
covariates were modeled using fractional change functions
(Eq. 2).




P ¼ h1  ð1 þ h2  COVÞ ð2Þ
where the hs are the parameters to be estimated. In Eq. 1,
h1 represents the typical value of pharmacokinetic param-
eter (P) in an individual with the median value for the
covariate and h2 represents the coefficient for particular
covariate effect. In Eq. 2, h1 represents the typical value of
pharmacokinetics parameter for an individual with covar-
iate value = 0 and h2 represents the fractional change in
pharmacokinetics parameter for an individual with covar-
iate value = 1 relative to covariate value = 0. A multi-
plicative covariate regression approach was implemented
during covariate model building.
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Improvement in the model at each step was assessed
based on reduction in OFV, improvement in goodness-of-
fit diagnostics, reduction in between and within-subject
variability, and improvement in parameter precision.
The performance of the final population pharmacoki-
netic model was evaluated using visual predictive check
(VPC) [32], a technique whereby model appropriateness is
tested by means of comparing prediction intervals of the
observed data to simulation data using the final population
model. The impact of body WT-based and fixed dosing of
sifalimumab was evaluated by comparing predicted median
steady state serum concentrations (Css), 5th and 95th per-
centiles using the final population model. A population of
1,000 SLE patients was simulated using covariate distri-
bution from study MI-CP152. The final population model
was utilized for predicting pharmacokinetic exposure fol-
lowing various fixed intravenous doses of sifalimumab to
support phase IIb dosing.
3 Results
3.1 Data
A total of 120 patients provided evaluable pharmacokinetic
data for the population analysis. The population pharma-
cokinetic data consisted of 2,370 sifalimumab serum con-
centrations following escalating doses of 0.3, 1.0, 3.0, and
10 mg/kg sifalimumab. On average, approximately 20
samples were available per patient, over a collection time
of up to 1 year. One patient from the 10 mg/kg cohort was
excluded from the analysis due to very low observed serum
concentrations compared with the average concentrations
in the 10 mg/kg cohort. The reasons for this low exposure
are unclear. Table 1 provides a summary of important
patient demographics and other baseline characteristics
included in the pharmacokinetic analysis. The patient
population was predominantly from North America (71 %)
and female (95 %), with a median age of 43 years and
median body WT of 73 kg. A total of eight subjects did not
have BGENE4 information available; hence a population
median value was imputed for these subjects.
3.2 Population Pharmacokinetic Modeling
A two-compartment model best described the sifalimumab
concentration-time data and was considered as the base
model. The pharmacokinetic model was parameterized
using clearance (CL), central volume of distribution (V1),
peripheral volume of distribution (V2) and the inter-com-
partmental clearance (Q). The between-subject variability
parameters (gs) were included for all the pharmacokinetic
parameters using exponential functions, whereas the
residual error was modeled using a proportional model.
Inclusion of the covariance terms gCL  gV1 and gV1  gV2
improved the fit significantly. The mean (% between-sub-
ject variability) estimates from the base model were as
follows: CL = 0.2 L/day (35 %); V1 = 2.88 L (33 %);
V2 = 2.12 L (60 %); and Q = 0.175 L/day (75 %). All
model parameters were estimated with good precision.
The covariate model evaluated the influence of age, sex,
ethnicity, region, body WT, BSTEROID, BSLEDAI,
BGENE21, BGENE4, and IM. In the final model,
BGENE21, body WT, BSTEROID, and sifalimumab dose
were identified as statistically significant covariates for the
sifalimumab CL. Body WT was also found to be a statis-
tically significant covariate for V1 and V2.
The final model functions for typical value of CL, V1, V2
and Q are presented as follows (Eqs. 3–6).









 1 þ h8  BSTEROIDð Þ
ð3Þ








Q ¼ h4 ð6Þ
where h1 is the CL of a typical/standard patient with body
WT = 75 kg, BGENE21 = 32, dose = 1 mg/kg, and
BSTEROID = 0. h2 and h3 represent the V1 and V2 of a
typical/standard subject with body WT = 75 kg, respec-
tively. h5–h10 are the exponents of covariate effect on
respective pharmacokinetic parameters.
The final population pharmacokinetic parameters are
presented in Table 2. The estimated values of CL, V1, V2, and
Q for a typical/standard patient were about 176 mL/day,
2.9 L, 2.12 L and 171 mL/day, respectively. The estimates
(coefficient of variation) of between-subject variability
associated with CL, V1, V2, and Q were 28, 31, 58, and 71 %,
respectively. The g-shrinkage was estimated to be 4 % (CL),
12 % (V1), 16 % (V2), and 39 % (Q). The e-shrinkage was
6 %. The condition number was 382. All pharmacokinetic
parameters were estimated with good precision, as reflected
by relative standard errors. The performance of the final
model fit is represented by goodness-of-fit plots as shown in
Fig. 1. Figure 1a, b show good agreement between observed
and model predicted [population predicted (PRED)/indi-
vidual predicted (IPRED)] sifalimumab serum concentra-
tions. The plots of conditional weighted residual (CWRES)
versus the PRED concentrations (Fig. 1c) or time (Fig. 1d)
do not show any obvious pattern.
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The coefficients of body WT effect on CL (h5), V1 (h9),
and V2 (h10) were 0.481, 0.489, and 0.646, respectively,
indicating a less than proportional increase in pharmaco-
kinetic parameters with body WT. Addition of body WT
reduced between-subject variability by 3, 2, and 3 % on
CL, V1, and V2, respectively. In addition to body WT,
sifalimumab CL was also impacted by changes in
BGENE21, BSTEROID, and sifalimumab dose. The
coefficients for the effect of BGENE21 (h6), BSTEROID
(h8), and sifalimumab dose (h7) on CL were estimated to be
0.0558, 0.195, and 0.0542, respectively. Inclusion of
BGENE21, BSTEROID, and sifalimumab dose as signifi-
cant covariates on CL explained about only 1.5, 1, and 2 %
of between-subject variability in CL. The CL of
sifalimumab changed from 135 to 221 mL/day over the
body WT range of 43–120 kg. Over the range of
BGENE21 scores (0.63–87), sifalimumab CL changed
from 141 to 186 mL/day. Sifalimumab CL changed from
165 to 199 mL/day over the dose range of 0.3–10 mg/kg.
Patients who received steroid therapy had 19.5 % higher
sifalimumab CL compared with subjects with no steroid
administration. Over the body WT range of 43–120 kg, V1
and V2 changed from 2.2 to 3.6 and 1.5 to 2.9 L,
respectively. Overall, inclusion of all the previously-men-
tioned covariates in the final population model explained
only about 7 % between-subject variability and key
pharmacokinetic parameters changed \30 %. The evalua-
tion of immunogenicity as a covariate demonstrated no
impact of anti-drug antibody (ADA) on sifalimumab
pharmacokinetics.
VPC results demonstrated good predictability of the
final population pharmacokinetic model. As shown in
Fig. 2, the observed median (solid red line), 5th and
95th data percentiles (dashed red lines) were ade-
quately captured by the corresponding simulation-based
prediction intervals (solid and dashed black lines) and
95 % confidence intervals (green and beige shaded
areas).





















Baseline body weight (kg) 120 76 (19) 73
(43.1–120)
Age (years) 120 42 (11) 43 (18–71)









120 81 (87) 56
(0.26–337)
Table 2 Population pharmacokinetic parameters of sifalimumab









CL {h1} (L/day) 0.176 (7) 28 (13) 4
V1 {h2} (L) 2.90 (3) 31 (19) 12
V2 {h3} (L) 2.12 (6) 58 (35) 16



































BGENE21 baseline gene signature from 21 genes, BSTEROID base-
line steroid use (0 = no and 1 = yes), CL linear clearance, CV
coefficient of variation, Q inter-compartmental clearance, RSE rela-
tive standard error, V1 central volume of distribution, V2 peripheral
volume of distribution, WT baseline body weight
PopPK of Sifalimumab in Patients with SLE 1021
3.2.1 Comparison of Fixed (mg) Versus Body Weight-
Based (mg/kg) Dosing
The impact of fixed versus body WT-based dosing was
evaluated by comparing 200 mg (fixed) with 3 mg/kg
(body WT-based) every 14-day dosing of sifalimumab in a
simulated SLE population of 1,000 patients. The fixed dose
of 200 mg was selected to approximate 3 mg/kg (based on
75 kg body WT). The body WT distribution (43–120 kg)
from MI-CP152 was used for the simulations. The final
population pharmacokinetic model was used to predict 5th,
median, and 95th percentile concentration-time profiles.
Simulation results demonstrate that both fixed and body
WT-based dosing regimens yield similar median Css and
overall variability as shown in Fig. 3.
3.2.2 Predicted Serum Concentrations for Phase IIb
Clinical Trial (MI-CP1067; NCT01283139)
The final population pharmacokinetic model was used to
predict concentration–time profiles following 200, 600, and
1,200 mg monthly (with an additional dose at Day 14) dose
of sifalimumab in a simulated SLE population of 1,000
patients. The predicted concentration-time profiles
(median, 5th, and 95th percentiles) are shown in Fig. 4.
The expected steady state pharmacokinetic exposure values
following 200, 600, and 1,200 mg monthly (with an addi-
tional dose at Day 14) dose of sifalimumab are presented in
Table 3.
4 Discussion
To improve the understanding of sifalimumab pharmaco-
kinetics, we developed a population pharmacokinetic
model to describe serum concentration-time data following
various doses of sifalimumab using a nonlinear mixed-
effects modeling approach. A further objective was to
identify patient/disease characteristics that influence
sifalimumab pharmacokinetic parameters. Systematic
understanding of the effect of patient/disease covariates
would allow more rational insight on the impact of dif-
ferent covariates on pharmacokinetics and the potential for
dose individualization for further development of
sifalimumab.
The elimination and degradation of mAbs occur pri-
marily via two mechanisms: (a) non-specific protein
catabolism by the reticuloendothelial system (RES) and
Fig. 1 Final model goodness-
of-fit plots for sifalimumab
serum concentrations. The thin
black line (diagonal and
horizontal) and thick black line
represent line of unity and loess
fit, respectively
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(b) specific binding to the target leading to complex
internalization (saturable target-mediated clearance) [33,
34]. It is anticipated that sifalimumab, a mAb that binds to
IFN-a, a soluble target, will exhibit linear pharmacoki-
netics [35]. In this population analysis, a two-compartment
model without target-mediated elimination adequately
Fig. 2 Visual predictive check
for sifalimumab serum
concentrations. Observed
median (solid red line), 5th and
9th percentiles (dashed red
lines) and corresponding
simulation-based prediction
intervals (solid and dashed
black lines) and 95 %

























Median (fixed dosing; 200 mg Q14D)
5th and 95th percentile (fixed dosing; 200 mg Q14D)
Median (WT-based dosing, 3 mg/kg Q14D)
5th and 95th percentile (WT-based dosing, 3 mg/kg Q14D)
Fig. 3 Similarity of predicted
pharmacokinetic profiles
(median, 5th and 95th
percentiles) following fixed
(200 mg every 14 days) and
body weight-based (3 mg/kg
every 14 days) dosing of
sifalimumab. Q14D every
14 days, WT body weight
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described sifalimumab concentration-time data. The esti-
mate of CL was about 176 mL/day for a typical individ-
ual, which is similar to the phase I study (MI-CP126) and
other mAbs [36–42]. Based on population pharmacoki-
netic modeling, sifalimumab distributes into a central
compartment volume (V1) of 2.9 L for a typical patient,
which is approximately equal to the plasma volume. The
V2 of 2.1 L suggests an apparently limited distribution
outside the vascular space, which is consistent with
behavior of endogenous IgG immunoglobulins and other
therapeutic mAbs [36–43]. Modest between-subject vari-
ability estimates of about 28 % (CL) and 31 % (V1) were
also in line with literature-reported values for other mAbs
[39–41]. Slightly higher between-subject variability was
estimated for V2 (58 %) and Q (71 %), which could be a
result of a non-uniform collection of primarily trough
blood samples. The estimated g-shrinkage and e-shrink-
age was \20 % for key parameters (except for Q) repre-
senting the informativeness of model diagnostics such as
Empirical Bayes Estimates (EBEs), IPRED, and CWRES.
The condition number of 382 implies that the model was
stable and was not overparameterized (condition number
\1,000).
Based on the covariate relationships, higher
sifalimumab CL was estimated for patients with higher
BGENE21, body WT, sifalimumab dose, and steroid use.
Both V1 and V2 also increased with increase in body WT.
The correlation of body WT with CL and volume of dis-
tributions has been shown for both small and large mole-
cules [39, 40, 42, 44, 45]. The coefficient/exponent of body
WT on CL, V1, and V2 were 0.481, 0.489, and 0.646,
respectively, resulting in a modest impact of body WT on
these parameters. Addition of body WT resulted in a minor
reduction in between-subject variability of about 3, 2, and
3 % in CL, V1, and V2, respectively. Over a wide range of
body WT (43–120 kg), relative to the typical individual,
only a \30 % change in key pharmacokinetic parameters
was estimated.
Patients with higher BGENE21 had slightly higher
clearance of sifalimumab. The elevated baseline type I IFN
gene signatures are an indicator of increased IFN-a levels
[18–20]. However, the impact of this covariate was not
substantial since only *1.5 % of between-subject vari-
ability was explained and CL changed by \20 % over the
range of BGENE21 scores. During covariate model
building, BGENE4 was also found to be a significant
covariate for sifalimumab CL. This was expected because
BGENE4 was a subset of BGENE21 and there was a high
degree of correlation between BGENE4 and BGENE21.
After accounting for the impact of BGENE21 in the model,
BGENE4 did not significantly influence the CL of
sifalimumab.
A slight increase in CL was estimated with increasing





















5000 Median (200 mg monthly)
5th and 95th percentiles (200 mg monthly)
Median (600 mg monthly)
5th and 95th percentiles (600 mg monthly)
Median (1200 mg monthly)
5th and 95th percentiles (1200 mg monthly)
Fig. 4 Predicted serum
concentrations following 200,
600, and 1,200 mg monthly
intravenous dosing of
sifalimumab (with single
loading dose at Day 14)
Table 3 Sifalimumab predicted median steady-state parameters fol-









200 89 18 1,110
600 268 53 3,329
1,200 536 106 6,659
AUCss area under the concentration-time curve at steady state, Cmax,ss
peak concentration at steady state, Ctrough,ss trough concentration at
steady state
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unclear at this point. The dose-dependent pharmacokinetics
were not expected and could be a data artifact since a
single-dose phase I study (MI-CP126) demonstrated linear
and dose proportional pharmacokinetics over the dose
range of 0.3–30 mg/kg. However, the impact of this
covariate was not clinically relevant because only about
2 % of between-subject variability in CL was explained
and the difference in CL between doses was within
variability.
Patients who received steroid therapy had 19.5 % higher
sifalimumab CL compared with subjects with no steroid
administration. Corticosteroids (e.g. methylprednisolone)
were used throughout the study to control the disease
activity. High disease activity in these patients might be
linked to higher type I IFN-a expression (or gene signa-
ture) [11, 14] and higher CL. However, addition of this
covariate accounted for only 1 % reduction in between-
subject variability in CL. The low titers of ADA did not
impact pharmacokinetics of sifalimumab.
Although the previously-mentioned covariates were
identified as statistically significant, they did not substan-
tially explain between-subject variability (\7 %) in phar-
macokinetic parameters. This suggests that a decrease or
increase in sifalimumab exposure over the range of these
covariates is not clinically relevant. Hence, no dosing
modifications are necessary to administer sifalimumab.
Other possible sources of variability might be related to
the elimination pathway of mAbs. mAbs are primarily
eliminated by RES through the interaction with neonatal Fc
receptors (FcRns). FcRns are expressed on phagocytic cells
of the RES and protect IgG from rapid clearance. Between-
subject variability in expression profiles and distribution of
FcRns could account for some of the variability in phar-
macokinetic profiles. However, information on these vari-
ables are lacking in the literature.
This study (MI-CP152) was designed to evaluate safety
and tolerability of sifalimumab in a SLE population fol-
lowing multiple intravenous administrations over the dose
range of 0.3 to 10 mg/kg. Measurements of clinical/disease
activity were included only as exploratory end points.
Sifalimumab demonstrated an acceptable safety and toler-
ability profile following multiple intravenous doses over
1 year. No statistically significant differences in clinical
activity (SLEDAI and British Isles Lupus Assessment
Group [BILAG] score) between sifalimumab and placebo
were observed. The heterogeneous baseline characteristics,
ascending dose design, and small number of patients in
each group made comparisons between groups difficult and
the study did not yield a clear estimate of target exposures.
The results of safety, tolerability, and preliminary clinical
activity of sifalimumab from the MI-CP152 study were
published recently [46].
Body size/WT-based dosing has been a common prac-
tice for large molecules including mAbs, therapeutic pro-
teins, and peptides. It is generally assumed that body-size
correction would reduce variability in pharmacokinetic
parameters across a wide range of patient body WTs. Body
WT-based dosing may lead to over-correction of body size
for low body WT patients and under-correction of body
size for patients with high body WT. A fixed dosing
approach is preferred by the prescribing community due to
ease of use and reduced dosing errors. In addition, patient
convenience and adherence can be greatly improved. In the
current population analysis, comparison of fixed versus
body WT-based dosing demonstrates that serum pharma-
cokinetic exposures and associated between-subject vari-
ability following both fixed and body WT-based dosing
were almost identical. Similar findings have been reported
by others [47–49]. Wang and colleagues investigated
12 mAbs and found that fixed and body size-based dosing
perform similarly, with fixed dosing being better for 7 of 12
antibodies [48]. In addition, they investigated 18 thera-
peutic proteins and peptides and showed that fixed dosing
performed better for 12 of 18 in terms of reducing the inter-
individual variability in pharmacokinetic/pharmacody-
namic parameters [49]. Our findings support the fixed
dosing regimen for future clinical studies of sifalimumab.
Given no major safety concerns, no clear target expo-
sure, and expectation of similar pharmacokinetic exposure,
we considered it feasible to switch to fixed dosing regimens
for evaluation in a phase IIb study. A wide range of doses
including 200, 600, and 1,200 mg sifalimumab was selec-
ted for the ongoing phase IIb study to evaluate the clinical
activity of sifalimumab. Population pharmacokinetic/
pharmacodynamic and exposure-response modeling of
clinical end point data from the ongoing phase IIb study are
planned in order to assess dose–response and guide phase
III dose selection for future pivotal studies of sifalimumab.
5 Conclusion
A two-compartment population pharmacokinetic model
adequately described the sifalimumab concentration-time
data in SLE patients. The estimated typical pharmacoki-
netic parameters were similar to other therapeutic mAbs
without target-mediated elimination. Although the popu-
lation analysis identified some statistically significant
covariates, they are not anticipated to be clinically relevant
because only \7 % between-subject variability in key
pharmacokinetic parameters was explained. The population
pharmacokinetic analysis also demonstrated the feasibility
of switching to fixed doses of sifalimumab in phase IIb
clinical trials.
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